Business
Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease
Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy ...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nResverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nCALGARY, Feb. 13, 2017\n\n\n\nEmergence of new potential indications for apabetalone (RVX-208) via third party research \n\n\n\nCALGARY, Feb. 13, 2017 /CNW/ - Resverlogix Corp. (\"Resverlogix\" or the \"Company\") (TSX: RVX) today highlighted two potentially new indications recently identified by third party academic research involving its lead drug, apabetalone.  The first indication was published in the Journal of Neuroinflammation which described the inhibition of bromodomain and extra-terminal (BET) epigenetic readers, including apabetalone (RVX-208), as having therapeutic potential in degenerative diseases of the eye (retinal).  The second indication was highlighted by research conducted at Saint Louis University, demonstrating apabetalone mediated modulation of important targets in Facioscapulohumeral Muscular Dystrophy (FSHD).  Both indications are areas of interest and licensing potential for Resverlogix. \n\n\"Due to the dramatic growth of BET Bromodomain publications over the past decade, it is not surprising that our advanced Phase 3 compound, apabetalone, is drawing expanded attention from the global academic community. Over the past decade BET Bromodomain publications have grown by over 2,700 percent. Resverlogix publications have increased even more dramatically during this same timeframe.\" stated Donald McCaffrey, President and Chief Executive Officer.\n\nFindings on Retinal Degeneration\n\nIn January 2017, the Journal of Neuroinflammation published an article titled \"Photoreceptor protection via blockade of BET epigenetic readers in a murine model of inherited retinal degeneration\" (Zhao et al. Journal of Neuroinflammation (2017) 14:14) where BET inhibitors, including apabetalone (RVX-208), were tested in an animal model of retinal degeneration. The authors concluded that inhibition of the epigenetic re...